These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10151739)

  • 1. Pharmacoeconomic issues in the treatment of depression.
    Cohen LJ
    Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
    Sheehan DV; Wright-Etter PJ
    Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
    Anton SF; Revicki DA
    Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic issues in the treatment of depression.
    Saklad SR
    Pharmacotherapy; 1995; 15(6 Pt 2):76S-83S. PubMed ID: 8587854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of paroxetine and imipramine in depressed outpatients.
    Melton ST; Kirkwood CK; Farrar TW; Brink DD; Carroll NV
    Psychopharmacol Bull; 1997; 33(1):93-100. PubMed ID: 9133757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.
    Jönsson B; Bebbington PE
    Br J Psychiatry; 1994 May; 164(5):665-73. PubMed ID: 7921718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and economic impact of antidepressant medications: a review.
    Mitchell J; Greenberg J; Finch K; Kovach J; Kipp L; Shainline M; Jordan N; Anderson C
    Am J Manag Care; 1997 Feb; 3(2):323-30; quiz 331. PubMed ID: 10169266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder.
    Burke MJ; Silkey B; Preskorn SH
    J Clin Psychiatry; 1994 Sep; 55 Suppl A():42-52; discussion 53-4, 98-100. PubMed ID: 7961542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada.
    Lapierre Y; Bentkover J; Schainbaum S; Manners S
    Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
    Serrano-Blanco A; Suárez D; Pinto-Meza A; Peñarrubia MT; Haro JM;
    J Eval Clin Pract; 2009 Feb; 15(1):195-203. PubMed ID: 19239602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost analysis of paroxetine versus imipramine in major depression.
    Bentkover JD; Feighner JP
    Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.
    Sado M; Knapp M; Yamauchi K; Fujisawa D; So M; Nakagawa A; Kikuchi T; Ono Y
    Aust N Z J Psychiatry; 2009 Jun; 43(6):539-47. PubMed ID: 19440886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are psychological treatments for depression in primary care cost-effective?
    Bosmans JE; van Schaik DJ; de Bruijne MC; van Hout HP; van Marwijk HW; van Tulder MW; Stalman WA
    J Ment Health Policy Econ; 2008 Mar; 11(1):3-15. PubMed ID: 18424872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The costs of depression: direct and indirect; treatment versus nontreatment.
    Panzarino PJ
    J Clin Psychiatry; 1998; 59 Suppl 20():11-4. PubMed ID: 9881536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of burning mouth syndrome therapy.
    Hens MJ; Alonso-Ferreira V; Villaverde-Hueso A; Abaitua I; Posada de la Paz M
    Community Dent Oral Epidemiol; 2012 Apr; 40(2):185-92. PubMed ID: 22044166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
    Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
    Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depression program found more effective but more costly than usual care.
    Levenson D
    Rep Med Guidel Outcomes Res; 2001 Oct; 12(19):1-2, 5. PubMed ID: 12374141
    [No Abstract]   [Full Text] [Related]  

  • 20. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.